Durvalumab (Imfinzi) approved in EU for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC)

Approval is for use in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, and is based on phase III CASPIAN trial, which reported overall survival benefit for combination vs. chemotherapy alone (13.0 vs. 10.3 months, respectively).